/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20chart%20-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Westbrook, Maine-based IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. With a market cap of $40.4 billion, the company operates through Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy segments.
Shares of IDXX have significantly lagged behind the broader market over the past 52 weeks. IDXX stock has dropped 2.8% over this period, while the broader S&P 500 Index ($SPX) has gained 10.2%. However, shares of IDXX are up 21.3% on a YTD basis, outpacing SPX’s 1.3% dip during the same time frame.
Looking closer, IDEXX Laboratories has outperformed the iShares U.S. Healthcare ETF’s (IYH) 10.4% decline over the past year and 6.5% fall in 2025.
IDEXX Laboratories' stock prices rose 9% following the release of its mixed Q1 2025 results on May 1. The company reported revenue of $998.4 million, up 3.6% year-over-year, driven by growth across all segments; however, it fell short of Wall Street expectations. The Companion Animal Group (CAG) segment saw solid performance, supported by 3% recurring revenue growth in CAG Diagnostics in both the U.S. and international markets. Gross profits increased 5.1% to $623.4 million. EPS came in at $2.96, marking a 5.3% rise from the prior-year quarter and surpassing analysts’ estimates by 1.4%.
Looking ahead to fiscal 2025, IDXX raised its guidance, boosting investor confidence. It now expects revenue to range between $4.1 billion and $4.21 billion, representing growth of 5% to 8%, up from the previous range of $4.06 billion to $4.17 billion. The company also raised its EPS forecast to a range of $11.93 to $12.43, compared to the prior guidance of $11.74 to $12.24.
For the current fiscal year 2025, ending in December, analysts expect IDXX's EPS to increase nearly 14% year-over-year to $12.16. The company has a mixed earnings surprise history. It beat the Street's bottom-line estimates in three of the past four quarters while missing on one occasion.
Among the 11 analysts covering IDXX stock, the consensus rating is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, one “Moderate Buy,” and four “Holds.”
This configuration has been stable in recent months.
On May 19, Stifel (SF) analyst Jonathan Block reiterated a “Hold” rating on IDXX and raised the price target from $460 to $510.
As of writing, IDEXX Laboratories’ mean price target of $529.50 implies a 5.6% premium to current price levels, while the Street-high target of $577 suggests a notable 15% upside potential.
